Hannah Valantine - Director, Bridgebio Pharma, Inc

As of June 24, 2022


What is Hannah Valantine's Net Worth?

The current estimated net worth of Bridgebio Pharma, Inc's Director, Hannah Valantine, is estimated to be about $55.14K . Hannah Valantine owns about 1,764 units of Bridgebio Pharma, Inc common stock. In the last year at Bridgebio Pharma, Inc, Hannah Valantine has sold an estimated value of $0 worth.

What is Hannah Valantine's Past Insider Trading?

Hannah Valantine's largest purchase order was 1,764 units , worth over $25.1K on January 3, 2022. In total, Hannah Valantine has made about 3 transactions over a year of their time at Bridgebio Pharma, Inc. Hannah Valantine usually trades in January, June and October, with the busiest year in 2022.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is Hannah Valantine's' Mailing Address?

  • Mailing address is 1305 O'Brien Drive Menlo Park CA 94025 CA

Bridgebio Pharma, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Compensation
Total
Neil Kumar, Ph.D. 2020 $550,000 $825,000 $2,368,511 $6,299,998 $11,400 $10,054,909
Neil Kumar, Ph.D. 2019 $502,765 $360,000 $13,863,445 $11,573,049 $34,804 $26,334,063
Neil Kumar, Ph.D. 2018 $450,000 - - - - $450,000
Brian Stephenson, Ph.D., CFA 2020 $550,000 $712,500 $789,494 $2,099,996 $11,943 $4,163,933
Brian Stephenson, Ph.D., CFA 2019 $420,000 $189,000 $132,600 $3,430,781 $26,586 $4,198,967
Brian Stephenson, Ph.D., CFA 2018 $74,375 $330,240 $1,942,500 - - $2,347,115
Michael Henderson, M.D. 2020 $515,000 $300,000 $7,072,500 $91,899 $11,843 $7,991,241
Cameron Turtle, Ph.D.* 2020 $400,000 $210,000 $3,940,081 - $11,400 $4,561,482
Charles Homcy, M.D. 2020 $500,000 $100,000 - $1,199,992 $55,812 $1,855,805
Charles Homcy, M.D. 2019 $513,808 - $2,111,579 $3,128,716 $221,737 $5,975,842
Brian Stolz 2020 $511,362 $25,000 $736,854 $1,992,182 $1,975,453 $5,240,851
Brian Stolz 2019 $146,780 $93,750 $6,860,780 $1,045,003 - $8,146,313
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1743881/000119312521145491/d131567ddef14a.htm

What are Bridgebio Pharma, Inc's Past Insider Trades?

Bridgebio Pharma, Inc's most recent insider trade came on March 17, 2022 by Andrea Ellis who bought 12,000 units worth $100.68K . In the last 3 years, insiders at Bridgebio Pharma, Inc have sold an estimated value of $351.74M and bought an estimated value of $213.34M worth of shares. Insider trading is most common in June, with the busiest year in 2020. The most active traders at the company are Neil Kumar, CEO and President,  Brian C Stephenson, See Remarks,  and Thomas Michael Henderson, Chief Business Officer .

BridgeBio Pharma, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1